Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.

Pozdnyakova O, Wu K, Patki A, Rodig SJ, Thiele J, Hasserjian RP.

Mod Pathol. 2014 Nov;27(11):1447-54. doi: 10.1038/modpathol.2014.69. Epub 2014 Apr 25.

2.

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.

Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O.

J Transl Med. 2015 Sep 10;13:294. doi: 10.1186/s12967-015-0644-4.

3.

[Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].

Tovar-Bobadilla JL, Ortiz-Hidalgo C.

Gac Med Mex. 2016 May-Jun;152(3):407-18. Review. Spanish.

4.

Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.

Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.

Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.

PMID:
25171702
5.

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, Rotunno G, Gisslinger H, Gisslinger B, Müllauer L, Finazzi G, Carobbio A, Gianatti A, Ruggeri M, Nichele I, D'Amore E, Rambaldi A, Tefferi A.

Blood. 2012 Mar 8;119(10):2239-41. doi: 10.1182/blood-2011-11-393819. Epub 2012 Jan 13.

6.

Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.

Thiele J, Kvasnicka HM.

Pathobiology. 2007;74(2):89-96. Review.

7.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
8.

The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.

Kirabo A, Park SO, Wamsley HL, Gali M, Baskin R, Reinhard MK, Zhao ZJ, Bisht KS, Keserű GM, Cogle CR, Sayeski PP.

Am J Pathol. 2012 Sep;181(3):858-65. doi: 10.1016/j.ajpath.2012.05.033. Epub 2012 Jul 13.

9.

Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.

Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, Wilson A, Prchal J, Salama ME.

Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):663-8. doi: 10.1097/PAI.0000000000000000.

11.

The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.

Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andréasson B.

Eur J Haematol. 2011 Feb;86(2):148-55. doi: 10.1111/j.1600-0609.2010.01548.x. Epub 2010 Dec 22.

PMID:
21059102
12.

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?

Tibes R, Mesa RA.

Leuk Lymphoma. 2011 Jul;52(7):1178-87. doi: 10.3109/10428194.2011.566952. Epub 2011 May 23. Review.

PMID:
21599574
13.

Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.

Georgii A, Buhr T, Buesche G, Kreft A, Choritz H.

Leuk Lymphoma. 1996 Sep;22 Suppl 1:15-29. Review.

PMID:
8951769
14.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
15.

The histopathology of chronic myeloproliferative diseases.

Georgii A, Buesche G, Kreft A.

Baillieres Clin Haematol. 1998 Dec;11(4):721-49. Review.

PMID:
10640214
16.

The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.

Tadmor T, Bejar J, Attias D, Mischenko E, Sabo E, Neufeld G, Vadasz Z.

Am J Hematol. 2013 May;88(5):355-8. doi: 10.1002/ajh.23409. Epub 2013 Mar 12.

17.

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.

Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.

FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.

PMID:
22051730
18.

Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms.

Pozdnyakova O, Hasserjian RP, Verstovsek S, Orazi A.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):253-61. doi: 10.1016/j.clml.2014.11.002. Epub 2014 Nov 18. Review.

PMID:
25515354
19.

[Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].

Campr V.

Cesk Patol. 2011 Jul;47(3):84-93. Review. Czech.

PMID:
21887923
20.

European consensus on grading bone marrow fibrosis and assessment of cellularity.

Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A.

Haematologica. 2005 Aug;90(8):1128-32.

Supplemental Content

Support Center